Importantly, we demonstrated that rolipram, a pan PDE4 inhibitor, relieved Ang II-induced hypertension mainly by inhibiting PDE4D in SMCs, which suggested that PDE4D might represent a potential therapeutic hypertension target (Fig. 8). Here, PDE4A is linked to hypertensive disorder.